OS Therapies Inc. Files Q2 2025 10-Q Report

TL;DR

OS Therapies Inc. filed its 10-Q for Q2 2025. Check financials.

AI Summary

OS Therapies Inc. filed its 10-Q for the quarterly period ended June 30, 2025. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations sector. Its principal executive offices are located in Grasonville, Maryland.

Why It Matters

This filing provides investors with an update on OS Therapies Inc.'s financial performance and operational status for the second quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly filing (10-Q) and does not inherently indicate new risks.

Key Numbers

• 20250630 — Quarter End Date (The report covers the period ending on this date.)
• 001-42195 — SEC File Number (Identifies the company's filing with the SEC.)

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• June 30, 2025 (date) — Quarterly period end date
• Delaware (jurisdiction) — State of incorporation
• 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
• Grasonville, Maryland (location) — Address of principal executive offices
• 001-42195 (commission_file_number) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share OSTX NYSE American Indicate

Filing Documents

• ea0252948-10q_ostherap.htm (10-Q) — 830KB
• ea025294801ex31-1_ostherap.htm (EX-31.1) — 7KB
• ea025294801ex31-2_ostherap.htm (EX-31.2) — 7KB
• ea025294801ex32_ostherap.htm (EX-32) — 6KB
• 0001213900-25-077916.txt ( ) — 5947KB
• osti-20250630.xsd (EX-101.SCH) — 65KB
• osti-20250630_cal.xml (EX-101.CAL) — 33KB
• osti-20250630_def.xml (EX-101.DEF) — 309KB
• osti-20250630_lab.xml (EX-101.LAB) — 580KB
• osti-20250630_pre.xml (EX-101.PRE) — 338KB
• ea0252948-10q_ostherap_htm.xml (XML) — 647KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. 1 Balance Sheets as of June 30, 2025 and December 31, 2024 (unaudited) 1 2 3 4 Notes to the Financial Statements (unaudited) 5

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations. 30

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 42

Controls and Procedures

Item 4. Controls and Procedures. 42

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings. 43

Risk Factors

Item 1A. Risk Factors. 43

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 43

Exhibits

Item 6. Exhibits. 44 i

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements OS Therapies Incorporated Balance Sheets (unaudited) June 30, 2025 December 31, 2024 Current Assets Cash $ 2,802,013 $ 5,533,527 Prepaid Expenses 751,963 - Total Current Assets 3,553,976 5,533,527 Long-Term Assets Fixed Assets (Net) 3,880 5,270 Patents (Net) 6,752,619 - TOTAL ASSETS $ 10,310,475 $ 5,538,797 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts Payable $ 2,702,724 $ 1,662,068 Accrued Expenses 380,310 521,010 Accrued Payroll and Payroll Taxes – Related Party - 97,257 Preferred Dividends Payable 375,000 375,000 Warrant Liability - 1,971,975 Total Current Liabilities 3,458,034 4,627,310 Long-Term Liabilities TEDCO Grant 100,000 100,000 Total Long-Term Liabilities 100,000 100,000 Total Liabilities 3,558,034 4,727,310 Commitments and contingencies (See Note 6) MEZZANINE EQUITY: Series A Convertible Preferred Stock, par value $ 0.001 , 2,500,000 shares authorized; 662,250 and 1,512,500 issued and outstanding, respectively 1,808,794 4,078,025 Total Mezzanine Equity 1,808,794 4,078,025 STOCKHOLDERS' EQUITY (DEFICIT) Common Stock A, par value $ 0.001 , 50,000,000 shares authorized; 29,664,916 and 20,869,908 issued and outstanding, respectively 29,665 20,870 Preferred Stock, par value $ 0.001 , 5,000,000 shares authorized; 0 and 0 issued and outstanding, respectively - - Additional paid-in capital 51,759,838 35,144,967 Accumulated deficit ( 46,845,856 ) ( 38,432,375 ) Total Stockholders' Equity (Deficit) 4,943,647 ( 3,266,538 ) TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) $ 10,310,475 $ 5,538,797 The accompanying notes are an integral part of these unaudited financial statements. 1 OS Therapies Incorporated (unaudited) For the three months ended For the three months ended For the six months ended For the six months ended June

View Full Filing

View this 10-Q filing on SEC EDGAR